Geratherm Medical AG

GME

Equity

ISIN DE0005495626 / Valor 1091371

Xetra (2024-11-21)

EUR 2.74+2.24%

Geratherm Medical AG
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Geratherm Medical AG is an international medical technology company with a focus on developing innovative products for stroke prevention. The company has a strong academic and clinical network that complements its core competencies in mathematics, physics, and medicine. Geratherm's products, including spirometry, pulmonary function tests, and cardiopulmonary stress tests, are all developed and produced in Germany to meet high quality standards for pulmonologists, cardiologists, internists, sports medicine specialists, and natural scientists. In addition to medical devices, Geratherm also offers consumer products under the Geratherm® brand, such as clinical thermometers, blood pressure monitors, and pregnancy tests, which are available in pharmacies, retail outlets, and online shops. The company also provides innovative solutions like the MR diagnostics incubator system nomag®IC advanced for newborns and premature babies, allowing for non-invasive magnetic resonance imaging. With products for both private and professional users in various healthcare settings, Geratherm aims to meet the diverse needs of its customers worldwide.

Summarized from source with an LLMView SourceSector: Healthcare

Sales Revenues

In the first quarter of 2023, Geratherm Medical AG reported sales revenues of TEUR 20,956, a decrease from TEUR 25,851 in the same quarter of 2022. This decline reflects a challenging market environment and potential shifts in product demand.

Gross Profit (EBITDA)

Geratherm Medical AG's gross profit (EBITDA) for Q1 2023 was TEUR 4,636, showing an improvement compared to TEUR 4,134 in Q1 2022. This increase indicates better cost management and operational efficiency despite lower sales revenues.

Operating Results (EBIT)

The operating results (EBIT) for Geratherm Medical AG in the first quarter of 2023 stood at TEUR 2,550, up from TEUR 2,072 in the same period of the previous year. This positive trend suggests effective control over operating expenses and improved profitability.

Results of Shareholders

For Q1 2023, Geratherm Medical AG reported results of shareholders amounting to TEUR 1,111, a slight increase from TEUR 1,023 in Q1 2022. This growth reflects the company's ability to generate value for its shareholders even in a challenging revenue environment.

Equity and Equity Ratio

As of the first quarter of 2023, Geratherm Medical AG's equity was TEUR 22,611, with an equity ratio of 63.3%. This is an improvement from the previous year's equity of TEUR 22,228 and an equity ratio of 57.9%, indicating a stronger financial position and stability.

Summarized from source with an LLMView Source

Key figures

-52.8%1Y

-71.7%3Y

-63.7%5Y

Performance

51.6%1Y

43.9%3Y

42.8%5Y

Volatility